David Staskin, MD

David Staskin, MD, was an Associate Professor of Urology and Director of the Section of Voiding Dysfunction at New York Presbyterian Hospital-Cornell (2002-2008) and Associate Professor of Urology, Harvard Medical School, Beth Israel Decaconess Medical Center (1989-2002). Dr. Staskin has expertise in pharmaceuticals (urologic - urogynecologic), in particular, overactive bladder and stress incontinence, phase II-IV pharmaceutical studies, physician education, new product market potential, urologic products, BPH, impotence, and surgical devices and gynecologic products in urogynecology. He is a former member of US Department of Health and Human Sciences-Agency for Health Care Policy and Research and Section Chairperson of ICI-WHO International Urinary Incontinence Guidelines. Dr. Staskin holds advisory positions with pharmaceutical companies such as Ortho-McNeil, Pfizer, Astellas, Indevus, Esprit, Novartis, Watson, GlaxoSmithKline, Eli Lilly, Proctor and Gamble, and American Medical Syst (This is me - Update Profile)